Solid Biosciences (SLDB) Other Accumulated Expenses (2017 - 2024)

Solid Biosciences has disclosed Other Accumulated Expenses across 7 years of filings, most recently posting $92000.0 for Q1 2024.

• Other Accumulated Expenses for Q1 2024 came in at $92000.0, up 67.27% year-over-year; the trailing twelve-month figure through Mar 2024 was $92000.0 (up 67.27% YoY), and the FY2023 annual result was $24000.0, up 71.43% from the prior year.
• Other Accumulated Expenses came in at $92000.0 for Q1 2024 at Solid Biosciences, up from $24000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $162000.0 in Q3 2023 to a low of $14000.0 in Q4 2022.
• The 4-year median for Other Accumulated Expenses is $67000.0 (2021), against an average of $74250.0.
• Peak annual rise in Other Accumulated Expenses reached 408.7% in 2023, while the deepest fall reached 63.33% in 2023.
• Solid Biosciences' Other Accumulated Expenses stood at $35000.0 in 2021, then slumped by 60.0% to $14000.0 in 2022, then jumped by 71.43% to $24000.0 in 2023, then jumped by 283.33% to $92000.0 in 2024.
• The last three Other Accumulated Expenses figures came in at $92000.0 (Q1 2024), $24000.0 (Q4 2023), and $162000.0 (Q3 2023), per Business Quant data.